Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 12/20 | 0.54 |
| ▸ | PRKCI | P41743 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27037067 | 0.89 | SIGMAR1 (0.52) | P2RX3SIGMAR1RXFP1 | |
| SCHEMBL29949064 | 0.84 | P2RX3 (0.60) | P2RX3SIGMAR1MKNK1 | |
| SCHEMBL29949132 | 0.84 | P2RX3 (0.68) | P2RX3SIGMAR1RXFP1MKNK1 | |
| SCHEMBL27037057 | 0.78 | SIGMAR1 (0.68) | SIGMAR1 | |
| SCHEMBL18358077 | 0.73 | P2RX3 (0.66) | P2RX3RXFP1MKNK1 | |
| SCHEMBL27037138 | 0.73 | SIGMAR1 (0.72) | P2RX3SIGMAR1RXFP1 | |
| SCHEMBL27037072 | 0.72 | SIGMAR1 (0.64) | P2RX3SIGMAR1RXFP1 | |
| SCHEMBL1017080 | 0.67 | KDM4E (0.76) | P2RX3RXFP1MKNK1 | |
| SCHEMBL24996003 | 0.67 | MKNK1 (0.66) | P2RX3MKNK1 | |
| SCHEMBL30879369 | 0.67 | MKNK1 (0.66) | P2RX3MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182489-A1 | New 5,6,7,8-Tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-06-06 | — | — | US | disclosed |
| EP-4308574-A1 | NEW 5,6,7,8-TETRAHYDROPYRIDO[4',3':4,5] THIENO[2,3-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022195022-A1 | NEW 5,6,7,8-TETRAHYDROPYRIDO[4',3':4,5] THIENO[2,3-d]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182489-A1 | New 5,6,7,8-Tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one Derivatives as Sigma Ligands | SIGMAR1, OPRD1, TMEM97 | P2RX3 14/4885PRKCI 1916/4885SIGMAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.